BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144
BioNTech | 6-K: BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
BioNTech | 6-K: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
BioNTech | 6-K: Lift of Partial Clinical Hold for BNT326/YL202
BioNTech | 6-K: Pfizer and BioNtech Provide Update on mRNA-Based Combination Vaccine Program Against Influenza and Covid-19 in Individuals 18-64 Years of Age
BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
BioNTech | 6-K: BioNTech SE Announced Positive Topline Data from the Ongoing Phase 2 Clinical Trial
BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
No Data
No Data